{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:24:50Z","timestamp":1785165890352,"version":"3.55.0"},"reference-count":81,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Aging","award":["P01 AG003991"],"award-info":[{"award-number":["P01 AG003991"]}]},{"name":"National Institute of Aging","award":["P01 AG026276"],"award-info":[{"award-number":["P01 AG026276"]}]},{"name":"National Institute of Aging","award":["P30 AG066444"],"award-info":[{"award-number":["P30 AG066444"]}]},{"name":"National Institute of Aging","award":["UL1TR002345"],"award-info":[{"award-number":["UL1TR002345"]}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG065234"],"award-info":[{"award-number":["R01 AG065234"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Returning research results that indicate risk of Alzheimer disease (AD) dementia\u2014a disease for which no meaningful treatments or cure exist\u2014to cognitively normal participants is controversial. AD is thought to begin many years before clinical signs and symptoms begin. During this time, individuals are cognitively normal but have biomarkers that indicate pathophysiological changes in the brain. With this study, we aim to evaluate the impact of returning research results on cognitively normal participants recruited from a longitudinal observational cohort on ageing at the Knight Alzheimer Disease Research Centre (Knight ADRC) at Washington University in St. Louis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Our study uses a 2-year, delayed-start randomised clinical trial design. Participants are randomised to receive their research results either 2 weeks or 1 year after informed consent. This study was approved to recruit up to 450 participants with existing genetic and biomarker testing results from the Knight ADRC. During the study period, 260 individuals were eligible and approached for entry into the study. The primary cognitive outcomes are 1-year change in subjective cognitive score on the clinical dementia rating sum of box scores and the objective cognitive score on cognitive composite score. The primary psychosocial outcome is change in geriatric depression scale score 1 year after return of research results. The study was powered to answer primary outcomes with 140 participants (70 per study arm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the Washington University School of Medicine (WUSM) Institutional Review Board and the Human Research Protection Office. Results from these trials are shared through conferences and publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04699786\">NCT04699786<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099970","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:15:19Z","timestamp":1767762919000},"page":"e099970","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["What is the psychological and cognitive impact of returning Alzheimer disease dementia research results to healthy research participants? a delayed-start randomised clinical trial protocol for the WeSHARE study (Washington University study of having Alzheimer disease\n                    <b>r<\/b>\n                    esearch results explained)"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04699786","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sarah M","family":"Hartz","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Washington University in Saint Louis, Saint Louis, Missouri, USA"},{"name":"Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9324-7434","authenticated-orcid":false,"given":"Spondita","family":"Goswami","sequence":"additional","affiliation":[{"name":"Bioethics Research Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Oliver","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University in Saint Louis, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University in Saint Louis, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University in Saint Louis, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Linnenbringer","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M","family":"Moulder","sequence":"additional","affiliation":[{"name":"Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Morris","sequence":"additional","affiliation":[{"name":"Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mozersky","sequence":"additional","affiliation":[{"name":"Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri, USA"},{"name":"Bioethics Research Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026010621151002000_16.1.e099970.1","unstructured":"National plan to address alzheimer\u2019s disease: 2017 update. 2017. Available: https:\/\/aspe.hhs.gov\/national-plan-address-alzheimers-disease-2015-update"},{"key":"2026010621151002000_16.1.e099970.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026010621151002000_16.1.e099970.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2026010621151002000_16.1.e099970.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.11.009"},{"key":"2026010621151002000_16.1.e099970.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2026010621151002000_16.1.e099970.6","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X"},{"key":"2026010621151002000_16.1.e099970.7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology (ECronicon)"},{"key":"2026010621151002000_16.1.e099970.8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jalz.2016.12.003","article-title":"Preclinical Alzheimer\u2019s disease: A systematic review of the cohorts underlying the concept","volume":"13","author":"Epelbaum","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2026010621151002000_16.1.e099970.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.241"},{"key":"2026010621151002000_16.1.e099970.10","unstructured":"GeneMatch: connecting alzheimer\u2019s prevention studies with eligible volunteers. n.d. Available: https:\/\/www.endalznow.org\/genematch"},{"key":"2026010621151002000_16.1.e099970.11","unstructured":"Alzheimer\u2019s prevention registry. n.d. Available: https:\/\/www.endalznow.org\/"},{"key":"2026010621151002000_16.1.e099970.12","unstructured":"The dominantly inherited alzheimer network. Washington University School of Medicine St Louis. n.d. Available: https:\/\/dian.wustl.edu\/our-research\/observational-study\/"},{"key":"2026010621151002000_16.1.e099970.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00645-6"},{"key":"2026010621151002000_16.1.e099970.14","doi-asserted-by":"crossref","unstructured":"Botkin JR , Mancher M , Busta ER , et al . Returning Individual Research Results to Participants: Guidance for a New Research Paradigm. The National Academies Press, 2018.","DOI":"10.17226\/25094"},{"key":"2026010621151002000_16.1.e099970.15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3233\/JAD-220810","article-title":"Disclosing Individual Results in Dementia Research: A Proposed Study Participant\u2019s Bill of Rights","volume":"90","author":"Walter","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"2026010621151002000_16.1.e099970.16","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/jamaneurol.2015.2875","article-title":"Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results","volume":"72","author":"Gooblar","year":"2015","journal-title":"JAMA Neurol"},{"key":"2026010621151002000_16.1.e099970.17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3233\/JAD-230359","article-title":"The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility","volume":"97","author":"Robillard","year":"2024","journal-title":"JAD"},{"key":"2026010621151002000_16.1.e099970.18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.14283\/jpad.2024.33","article-title":"A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants","volume":"11","author":"Erickson","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026010621151002000_16.1.e099970.19","unstructured":"Alzheimer\u2019s association . Special report american perspectives on early detection of alzheimer\u2019s disease in the era of treatment. 2025."},{"key":"2026010621151002000_16.1.e099970.20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3233\/JAD-230359","article-title":"The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility","volume":"97","author":"Robillard","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"2026010621151002000_16.1.e099970.21","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12483","article-title":"Communicating Alzheimer\u2019s biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes","volume":"10","author":"Erickson","year":"2024","journal-title":"A&D Transl Res & Clin Interv"},{"key":"2026010621151002000_16.1.e099970.22","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13410"},{"key":"2026010621151002000_16.1.e099970.23","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12413","article-title":"Feasibility of virtual Alzheimer\u2019s biomarker disclosure: Findings from an observational cohort","volume":"9","author":"Erickson","year":"2023","journal-title":"A&D Transl Res & Clin Interv"},{"key":"2026010621151002000_16.1.e099970.24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1212\/WNL.0000000000206891","article-title":"Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum","volume":"100","author":"Largent","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026010621151002000_16.1.e099970.25","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200265","article-title":"Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial","volume":"14","author":"Grill","year":"2024","journal-title":"Neurol Clin Pract"},{"key":"2026010621151002000_16.1.e099970.26","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000016"},{"key":"2026010621151002000_16.1.e099970.27","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70535","article-title":"Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026010621151002000_16.1.e099970.28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.26838","article-title":"Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals","volume":"95","author":"Bonomi","year":"2024","journal-title":"Ann Neurol"},{"key":"2026010621151002000_16.1.e099970.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-024-03485-9","article-title":"Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center","volume":"11","author":"Fernandez","year":"2024","journal-title":"Sci Data"},{"key":"2026010621151002000_16.1.e099970.30","doi-asserted-by":"publisher","DOI":"10.1038\/S41582-024-00977-5"},{"key":"2026010621151002000_16.1.e099970.31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.14283\/jpad.2024.125","article-title":"Longitudinal Trajectories of the Cognitive Function Index in the A4 Study","volume":"11","author":"Amariglio","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026010621151002000_16.1.e099970.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14606","article-title":"Inclusion of Underrepresented Groups in Preclinical Alzheimer Disease Trials-Opportunities Abound","volume":"4","author":"Manly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026010621151002000_16.1.e099970.33","unstructured":"Self BJ . Senility, and Alzheimer\u2019s Disease in Modern America: A History. Johns Hopkins University Press, 2006."},{"key":"2026010621151002000_16.1.e099970.34","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldr023"},{"key":"2026010621151002000_16.1.e099970.35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.0b013e318232ac1a","article-title":"Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease","volume":"77","author":"Karlawish","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2026010621151002000_16.1.e099970.36","unstructured":"Discussion paper on ethical issues linked to the changing definitions\/use of terms related to Alzheimer\u2019s disease. 2016."},{"key":"2026010621151002000_16.1.e099970.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.08.003"},{"key":"2026010621151002000_16.1.e099970.38","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12010"},{"key":"2026010621151002000_16.1.e099970.39","unstructured":"Aschenbrenner AJ , Hassenstab J , McDade E , et al . n.d. Does knowledge of mutation status alter disease progression in autosomal dominant alzheimer disease? manuscript in preparation."},{"key":"2026010621151002000_16.1.e099970.40","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12121590"},{"key":"2026010621151002000_16.1.e099970.41","unstructured":"All of Us Research Program . Precision medicine initiative: privacy and trust principles. National Institutes of Health; 2018. Available: https:\/\/allofus.nih.gov\/about\/program-overview\/precision-medicine-initiative-privacy-and-trust-principles"},{"key":"2026010621151002000_16.1.e099970.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0398-3","article-title":"Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review","volume":"10","author":"de Wilde","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2026010621151002000_16.1.e099970.43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jalz.2015.09.005","article-title":"Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability","volume":"12","author":"Lim","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2026010621151002000_16.1.e099970.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.01.022"},{"key":"2026010621151002000_16.1.e099970.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809578"},{"key":"2026010621151002000_16.1.e099970.46","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jalz.2014.10.014","article-title":"A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer\u2019s disease","volume":"11","author":"Green","year":"2015","journal-title":"Alzheimer's & Dementia"},{"key":"2026010621151002000_16.1.e099970.47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-016-0212-z","article-title":"Psychological, behavioral and social effects of disclosing Alzheimer\u2019s disease biomarkers to research participants: a systematic review","volume":"8","author":"Bemelmans","year":"2016","journal-title":"Alz Res Therapy"},{"key":"2026010621151002000_16.1.e099970.48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WAD.0000000000000490","article-title":"Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results","volume":"36","author":"Erickson","year":"2022","journal-title":"Alzheimer Disease & Associated Disorders"},{"key":"2026010621151002000_16.1.e099970.49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3233\/JAD-215710","article-title":"Retaining Participants in Longitudinal Studies of Alzheimer\u2019s Disease","volume":"87","author":"Gabel","year":"2022","journal-title":"JAD"},{"key":"2026010621151002000_16.1.e099970.50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-220861","article-title":"A Qualitative Examination of Knowledge, Experiences, and Considerations of PET Brain Scan Participation Among Older Black and Latino Adults","volume":"91","author":"Glover","year":"2023","journal-title":"JAD"},{"key":"2026010621151002000_16.1.e099970.51","unstructured":"Hartz SM , Mozersky J , Linnenbringer E , et al . Development and validation of a risk calculator for Alzheimer disease dementia (under review). JAMA Neurol 2020."},{"key":"2026010621151002000_16.1.e099970.52","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2026010621151002000_16.1.e099970.53","unstructured":"Harkins KKJ . Disclosing Amyloid Status to a Person Without Cognitive Impairments. Pract Neurol 2018."},{"key":"2026010621151002000_16.1.e099970.54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3233\/JAD-200993","article-title":"Communicating 5-Year Risk of Alzheimer\u2019s Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results","volume":"79","author":"Mozersky","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"2026010621151002000_16.1.e099970.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"2026010621151002000_16.1.e099970.56","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.11.2412-a"},{"key":"2026010621151002000_16.1.e099970.57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/1097-4679(199403)50:2<256::AID-JCLP2270500218>3.0.CO;2-E","article-title":"Validation of the Geriatric Depression Scale--Short Form among inpatients","volume":"50","author":"Lesher","year":"1994","journal-title":"J Clin Psychol Mar"},{"key":"2026010621151002000_16.1.e099970.58","unstructured":"Weiss DS , Marmar CR . The impact of event scale - revised. In: Wilson J , Keane TM , eds. Assessing psychological trauma and ptsd. Guilford, 1996."},{"key":"2026010621151002000_16.1.e099970.59","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03256005"},{"key":"2026010621151002000_16.1.e099970.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00261-4"},{"key":"2026010621151002000_16.1.e099970.61","doi-asserted-by":"publisher","DOI":"10.1177\/0891988705281883"},{"key":"2026010621151002000_16.1.e099970.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2016.03.004"},{"key":"2026010621151002000_16.1.e099970.63","first-page":"127","article-title":"Illness representations among first-degree relatives of people with Alzheimer disease. Alzheimer disease and associated disorders","volume":"14","author":"Roberts","year":"2000","journal-title":"Jul-Sep"},{"key":"2026010621151002000_16.1.e099970.64","doi-asserted-by":"publisher","DOI":"10.1037\/0882-7974.17.1.125"},{"key":"2026010621151002000_16.1.e099970.65","doi-asserted-by":"publisher","DOI":"10.1097\/MRR.0b013e32829fb3db"},{"key":"2026010621151002000_16.1.e099970.66","doi-asserted-by":"publisher","DOI":"10.2307\/2955424"},{"key":"2026010621151002000_16.1.e099970.67","doi-asserted-by":"publisher","DOI":"10.2307\/2676360"},{"key":"2026010621151002000_16.1.e099970.68","unstructured":"National Academies of Sciences E, and Medicine . Returning individual results to participants: guidance for a new research paradigm. 2018."},{"key":"2026010621151002000_16.1.e099970.69","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/alz.12620","article-title":"Moving beyond disclosure: Stages of care in preclinical Alzheimer\u2019s disease biomarker testing","volume":"18","author":"Ketchum","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2026010621151002000_16.1.e099970.70","doi-asserted-by":"crossref","DOI":"10.1002\/dad2.12339","article-title":"Implications of preclinical Alzheimer\u2019s disease biomarker disclosure for US policy and society","volume":"14","author":"Erickson","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"2026010621151002000_16.1.e099970.71","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamaneurol.2022.1307","article-title":"Disclosing Alzheimer Disease Biomarker Results to Research Participants","volume":"79","author":"Grill","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026010621151002000_16.1.e099970.72","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaneurol.2020.2734","article-title":"Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment","volume":"77","author":"Grill","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026010621151002000_16.1.e099970.73","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/alz.12781","article-title":"A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer\u2019s disease dementia","volume":"19","author":"Hartz","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2026010621151002000_16.1.e099970.74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026010621151002000_16.1.e099970.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2014.06.064"},{"key":"2026010621151002000_16.1.e099970.76","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3129"},{"key":"2026010621151002000_16.1.e099970.77","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/brain\/awv046","article-title":"Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis","volume":"138","author":"Wang","year":"2015","journal-title":"Brain (Bacau)"},{"key":"2026010621151002000_16.1.e099970.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2016.12.026"},{"key":"2026010621151002000_16.1.e099970.79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010459107"},{"key":"2026010621151002000_16.1.e099970.80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010461107"},{"key":"2026010621151002000_16.1.e099970.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.07.010"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:15:28Z","timestamp":1767762928000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2025-099970"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099970","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}